Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  2018-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jgh.13852PMID 28671712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial

  2017cited by this paper
• Low serum transferrin correlates with acute‐on‐chronic organ failure and indicates short‐term mortality in decompensated cirrhosis

  2017cited by this paper
• The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection

  2016cited by this paper
• Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing

  2016cited by this paper
• Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis

  2016cited by this paper
• Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure

  2016cited by this paper
• The developing hypopharyngeal microbiota in early life

  2016cited by this paper
• Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis

  2016cited by this paper
• Coping with copper: legacy effect of copper on potential activity of soil bacteria following a century of exposure.

  2016cited by this paper
• Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.

  2016cited by this paper
• The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline

  2015cited by this paper
• Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

  2015cited by this paper
• Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol‐related acute‐on‐chronic liver failure

  2015cited by this paper
• Association of markers of bacterial translocation with immune activation in decompensated cirrhosis

  2014cited by this paper
• Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy

  2014cited by this paper
• Supplemental Figure 4

  2014cited by this paper
• Pathological bacterial translocation in liver cirrhosis.

  2014cited by this paper
• Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.

  2014cited by this paper
• Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.

  2014cited by this paper
• Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

  2013cited by this paper
• UPARSE: highly accurate OTU sequences from microbial amplicon reads

  2013influential reference
• Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis

  2012cited by this paper
• Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse

  2012cited by this paper
• Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites.

  2012cited by this paper
• How deep is deep enough for RNA-Seq profiling of bacterial transcriptomes?

  2012cited by this paper
• Is bacterial DNA a better marker than endotoxin of bacterial translocation in decompensated cirrhosis?

  2011cited by this paper
• Metagenomic biomarker discovery and explanation

  2011cited by this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.

  2011cited by this paper
• Human oral, gut, and plaque microbiota in patients with atherosclerosis

  2010cited by this paper
• QIIME allows analysis of high-throughput community sequencing data

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double‐blind placebo‐controlled crossover trial

  2009cited by this paper
• PyNAST: a flexible tool for aligning sequences to a template alignment

  2009cited by this paper
• FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix

  2009cited by this paper
• Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis

  2008cited by this paper
• TLR4 enhances TGF-beta signaling and hepatic fibrosis.

  2007cited by this paper
• Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M.

  2006cited by this paper
• Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential

  2005cited by this paper
• Rifaximin: In vitro and in vivo Antibacterial Activity – A Review

  2005cited by this paper
• Toll‐Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells

  2003cited by this paper
• Increased tumour necrosis factor α production in mesenteric lymph nodes of cirrhotic patients with ascites

  2003cited by this paper
• The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis

  2003cited by this paper
• Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement

  2003cited by this paper
• Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis

  2002cited by this paper
• Detection and identification of bacterial DNA in patients with cirrhosis and culture‐negative, nonneutrocytic ascites

  2002cited by this paper
• Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats

  1998cited by this paper
• Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation.

  1996cited by this paper
• Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation.

  1995cited by this paper
• A new kinetic single-stage Limulus amoebocyte lysate method for the detection of endotoxin in water and plasma.

  1993cited by this paper
• Serum levels of cytokines in chronic liver diseases.

  1992cited by this paper

• Comprehensive Insights into hepatic encephalopathy pathophysiology, epidemiology, diagnosis and management

  2025cites this paper
• Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.

  2025cites this paper
• Rifaximin reduces gut-derived inflammation in severe acute pancreatitis: an experimental animal model and randomized controlled trial

  2025cites this paper
• Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions

  2025cites this paper
• Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.

  2025cites this paper
• Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction

  2024cites this paper
• Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial.

  2024cites this paper
• HLA evolutionary divergence effect on bacterial infection risk in cirrhotic liver transplant candidates.

  2024cites this paper
• Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial

  2024cites this paper
• The causal effect of gut microbiota on hepatic encephalopathy: a mendelian randomization analysis

  2024cites this paper
• Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosis

  2024cites this paper
• Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis

  2023cites this paper
• Potential therapies for acute‐on‐chronic liver failure

  2023cites this paper
• Comparison of Inflammatory Cytokine Levels in Hepatic and Jugular Veins of Patients with Cirrhosis

  2023cites this paper
• Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial

  2023influential citation
• Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis

  2023cites this paper
• Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease

  2023cites this paper
• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

  2023cites this paper
• Rifaximin may induce rifampicin resistance in coagulase‐negative staphylococci

  2023cites this paper
• Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota

  2023cites this paper
• Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis

  2023cites this paper
• Endotoxin Translocation and Gut Barrier Dysfunction Are Related to Variceal Bleeding in Patients With Liver Cirrhosis

  2022cites this paper
• The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial

  2022cites this paper
• Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases.

  2022cites this paper
• Gut microbiota modulation in acute decompensation of liver cirrhosis: theory and therapeutic potential

  2022cites this paper
• Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions

  2022cites this paper
• Rifaximin stimulates nitrogen detoxification by PXR‐independent mechanisms in human small intestinal organoids

  2022cites this paper
• World Journal of Gastroenterology Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental

  2022cites this paper
• An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin

  2022cites this paper
• Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double‐blind controlled trial

  2021cites this paper
• The microbiota in cirrhosis and its role in hepatic decompensation.

  2021cites this paper
• Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction

  2021cites this paper
• Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.

  2021cites this paper
• The Use of Rifaximin in Patients With Cirrhosis

  2021cites this paper
• The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure

  2021cites this paper
• The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis.

  2021influential citation
• The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt

  2021cites this paper
• The bacterial spectrum of spontaneous bacterial peritonitis in patients with cirrhosis of liver.

  2020cites this paper
• Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

  2020cites this paper
• Gut microbiota derived propionate regulates the expression of Reg3 mucosal lectins and ameliorates experimental colitis in mice.

  2020cites this paper
• Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients

  2020cites this paper
• Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis

  2020cites this paper
• Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.

  2020cites this paper
• Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure

  2020cites this paper
• Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

  2019cites this paper
• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL ASSESSING SAFETY OF TWO DIFFERENT DOSES OF SIMVASTATIN IN COMBINATION WITH RIFAXIMIN IN DECOMPENSATED CIRRHOSIS

  2019cites this paper
• Faecal microbiota from patients with cirrhosis has a low capacity to ferment non‐digestible carbohydrates into short‐chain fatty acids

  2019cites this paper
• Rifaximin‐altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials

  2019cites this paper
• Gut-liver axis signaling in portal hypertension

  2019cites this paper
• Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2019cites this paper
• Alcohol or Gut Microbiota: Who Is the Guilty?

  2019cites this paper
• Medikamentöse Langzeittherapien zur Prognoseverbesserung bei Leberzirrhose und zur Vermeidung von Komplikationen der portalen Hypertension

  2019influential citation
• Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy

  2019cites this paper
• Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art

  2019cites this paper
• Mikrobiota und Reizdarmsyndrom – eine kritische Bestandsaufnahme

  2019cites this paper
• Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

  2019cites this paper
• Novel Targets and Drug Development in Portal Hypertension

  2019cites this paper
• Managing portal hypertension in patients with liver cirrhosis

  2018cites this paper
• Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

  2018cites this paper
• Animal Models When Examining the Gut-Liver Axis

  2018cites this paper
• Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure

  2018cites this paper
• No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial

  2018cites this paper
• Novel perspectives in the management of decompensated cirrhosis

  2018cites this paper
• Stability and resilience of the intestinal microbiota in children in daycare – a 12 month cohort study

  2018cites this paper
• Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

  2017cites this paper
• Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis

  year unknowncites this paper
• Metagenomes of blood and psoriatic skin. Research project. e2.2

  year unknowncites this paper